Latest Biogen Idec Stories
MarketOptimizer.org adds “Multiple Sclerosis Global Clinical Trials Review, H2, 2014” to its store.
RICHMOND, Calif., July 23, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
Genzyme/Sanofi's Lemtrada and Genentech/Roche's Ocrelizumab Will Likely Be Reserved for Patients with Aggressive/Severe MS, According to Findings from Decision Resources Group BURLINGTON, Mass.,
RICHMOND, Calif., July 16, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
Editor Note: For more information about this release, please scroll to bottom. LONDON, July 7, 2014 /PRNewswire/ -- On Thursday, July 03, 2014, the NASDAQ Composite
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
MISSISSAUGA, ON, June 25, 2014 /CNW/ - Biogen Idec Canada announces today that TECFIDERA(TM) (dimethyl fumarate) is now available for reimbursement in British Columbia (B.C.) through B.C.
AMSTERDAM and PETACH TIKVA, Israel, June 18, 2014 /PRNewswire/ -- uniQure N.V.
CARLSBAD, Calif., June 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
Current Neurologist-Reported Patient Share for Tecfidera Exceeds that of Genzyme's Aubagio and Novartis's Gilenya Combined, According to Findings from Decision Resources Group BURLINGTON, Mass.,
- An armed gangster.